Medical Marijuana Inc. Records Nearly $21 Million in Revenue for Q2 2019

  • In year-over-year revenue, Medical Marijuana, Inc. experienced over 30% growth.
  • According to the CEO, the second quarter of this year has been the most lucrative in the history of the company.

In the United States, the first publicly traded cannabis company is Medical Marijuana, Inc., and they’ve been an integral part of launching the first-ever cannabis-derived nutraceutical products, brand, and supply chain in the world. Now, according to PR Newswire, the company announced its financial results for Q2 2019, which ended on June 30th, 2019, revealing massive gains.

One of the big changes in this quarter is the record revenue of $20.7 million, which is over 30% higher than what the company brought in during the same quarter last year. From operations, the company generated $1.4 million in profits, achieving a gross profit of $15.4 million during the second quarter. This gross profit is 61% higher than what the company saw last year.

The company decreased in their general and administrative expenses, going from 21% of sales to 16% of sales. While Medical Marijuana experienced a loss of $2 million in this period last year, the net ordinary income for Q2 2019 was $877,964 this year.

Kannaway, a subsidiary of Medical Marijuana, was recognized as a top revenue-generating direct selling company by Direct Selling News and won a Gold Stevie Award for Medium Company of the Year in the Health Products and Services Category. This accolade was given to Kannaway at the 17th Annual American Business Awards.

Speaking on all of this progress, CEO Dr. Stuart Titus of Medical Marijuana, Inc. expressed that the company is “excited” to continue with this upward trajectory of success. He noted that this quart has experience the “largest sales revenue quarter in the history of our Company.” Dr. Titus added that the company aims to remain at the forefront of the market, stating that Arcview Market Research predicts a valuation of $57 billion for the cannabis industry in the next eight years.

Phyllis Milka

Phyllis Milka is one of the newest contributors here at TOC and has a diverse, multi-year background with his experienced writing career. Be sure to stay on the lookout for what she is going to help create here.

Share

Recent Posts

  • Gummies

Condor CBD Gummies – Shocking Customer Scam Concerns?

The Condor CBD Gummies have been the talk of the hemp-derived cannabidiol edibles as of…

2 years ago
  • Guides

Best Delta 8 THC Products – And Why You Need To Try Them

Delta 8 THC is a naturally occurring cannabinoid commonly produced from hemp-derived CBD. It’s relatively…

3 years ago
  • Guides

VidaCap: What To Know About the Best Mushroom Supplements Brand

With more people turning towards natural remedies in recent years, mushroom supplements have taken the…

3 years ago
  • Topicals & Salves

Circle Labs CBD: Legit Hemp Pain Relief Balm That Works?

The Circle Labs CBD Balm is extracted using a cold-infusion process and is an effective…

3 years ago
  • Gummies

Kara’s Orchards CBD Gummies: Safe Full Spectrum Hemp Extract

If anyone is looking for a CBD supplement that is packed with all the necessary…

3 years ago
  • Tinctures & Drops

Sage Elixir CBD: Legit Sage Elixir CBD Oil Tincture or Not?

If anyone has been searching the internet for all the benefits of CBD and where…

3 years ago